Literature DB >> 20005572

Short- and long-term changes in gene expression mediated by the activation of TLR9.

Sven Klaschik1, Debra Tross, Hidekazu Shirota, Dennis M Klinman.   

Abstract

CpG DNA binds to Toll-like receptor 9 to stimulate a strong innate immune response. The magnitude, duration and scope of CpG-induced changes in gene expression are incompletely understood despite extensive studies of TLR9 mediated signal transduction pathways. In particular, the prolonged effects of CpG DNA on gene activation have not been investigated despite evidence that a single dose of CpG DNA alters immune reactivity for several weeks. This study used gene expression analysis to monitor changes in mRNA levels for 14 days, and identified the genes, pathways and functional groups triggered in vivo following CpG DNA administration. Two discrete peaks of gene activation (at 3h and 5 days) were observed after CpG injection. Both the behavior and function of genes activated during the second peak differed from those triggered shortly after CpG administration. Initial gene up-regulation corresponded to a period when TLR9 ligation stimulated genes functionally associated with the generation of innate and adaptive immune responses (e.g. the NF-kappaB and B-cell receptor pathways). The second peak reflected processes associated with cell division (e.g. cell cycle and DNA replication and repair). The complex bimodal pattern of gene expression elicited by CpG DNA administration provides novel insights into the long-term effects of TLR9 engagement on genes associated with immunity and cell proliferation. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20005572      PMCID: PMC2830361          DOI: 10.1016/j.molimm.2009.11.014

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  52 in total

1.  Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation.

Authors:  Yee Hwa Yang; Sandrine Dudoit; Percy Luu; David M Lin; Vivian Peng; John Ngai; Terence P Speed
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

2.  An immunostimulatory oligodeoxynucleotide containing a cytidine-guanosine motif protects senescence-accelerated mice from lethal influenza virus by augmenting the T helper type 1 response.

Authors:  Li Dong; Isamu Mori; Md Jaber Hossain; Beixing Liu; Yoshinobu Kimura
Journal:  J Gen Virol       Date:  2003-06       Impact factor: 3.891

3.  Regulation of gene expression in mouse macrophages stimulated with bacterial CpG-DNA and lipopolysaccharide.

Authors:  Jian Jun Gao; Veronica Diesl; Tatiana Wittmann; David C Morrison; John L Ryan; Stefanie N Vogel; Maximillian T Follettie
Journal:  J Leukoc Biol       Date:  2002-12       Impact factor: 4.962

Review 4.  Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases.

Authors:  Anthony Adam Horner; Eyal Raz
Journal:  J Allergy Clin Immunol       Date:  2002-11       Impact factor: 10.793

5.  Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling.

Authors:  Masahiro Yamamoto; Shintaro Sato; Kiyotoshi Mori; Katsuaki Hoshino; Osamu Takeuchi; Kiyoshi Takeda; Shizuo Akira
Journal:  J Immunol       Date:  2002-12-15       Impact factor: 5.422

6.  CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection.

Authors:  Daniela Verthelyi; Mayda Gursel; Richard T Kenney; Jeffrey D Lifson; Shuying Liu; Joan Mican; Dennis M Klinman
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

7.  Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells.

Authors:  F Takeshita; C A Leifer; I Gursel; K J Ishii; S Takeshita; M Gursel; D M Klinman
Journal:  J Immunol       Date:  2001-10-01       Impact factor: 5.422

Review 8.  CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma.

Authors:  Antoine F Carpentier; Gregor Auf; Jean-Yves Delattre
Journal:  Front Biosci       Date:  2003-01-01

9.  Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2.

Authors:  Ali A Ashkar; Stefan Bauer; William J Mitchell; Jeff Vieira; Kenneth L Rosenthal
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

10.  A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant.

Authors:  Scott A Halperin; Gary Van Nest; Bruce Smith; Simin Abtahi; Heather Whiley; Joseph J Eiden
Journal:  Vaccine       Date:  2003-06-02       Impact factor: 3.641

View more
  20 in total

1.  Activation of type I interferon-dependent genes characterizes the "core response" induced by CpG DNA.

Authors:  Folkert Steinhagen; Corinna Meyer; Debra Tross; Mayda Gursel; Takahiro Maeda; Sven Klaschik; Dennis M Klinman
Journal:  J Leukoc Biol       Date:  2012-07-02       Impact factor: 4.962

2.  TLR7 and TLR9 ligands regulate antigen presentation by macrophages.

Authors:  Teja Celhar; Selma Pereira-Lopes; Susannah I Thornhill; Hui Yin Lee; Manprit K Dhillon; Michael Poidinger; John E Connolly; Lina H K Lim; Subhra K Biswas; Anna-Marie Fairhurst
Journal:  Int Immunol       Date:  2015-11-13       Impact factor: 4.823

3.  Regulation of the maturation of human monocytes into immunosuppressive macrophages.

Authors:  Defne Bayik; Debra Tross; Lydia A Haile; Daniela Verthelyi; Dennis M Klinman
Journal:  Blood Adv       Date:  2017-12-04

4.  Identification of novel innate immune genes by transcriptional profiling of macrophages stimulated with TLR ligands.

Authors:  Ivana V Yang; Weiwen Jiang; Holly R Rutledge; Brad Lackford; Laura A Warg; Lesly De Arras; Scott Alper; David A Schwartz; David S Pisetsky
Journal:  Mol Immunol       Date:  2011-06-12       Impact factor: 4.407

5.  A suppressive oligodeoxynucleotide expressing TTAGGG motifs modulates cellular energetics through the mTOR signaling pathway.

Authors:  Volkan Yazar; Gizem Kilic; Ozlem Bulut; Tugce Canavar Yildirim; Fuat C Yagci; Gamze Aykut; Dennis M Klinman; Mayda Gursel; Ihsan Gursel
Journal:  Int Immunol       Date:  2020-01-09       Impact factor: 4.823

Review 6.  CpG DNA as a vaccine adjuvant.

Authors:  Christian Bode; Gan Zhao; Folkert Steinhagen; Takeshi Kinjo; Dennis M Klinman
Journal:  Expert Rev Vaccines       Date:  2011-04       Impact factor: 5.217

7.  Inhibitory/suppressive oligodeoxynucleotide nanocapsules as simple oral delivery devices for preventing atopic dermatitis in mice.

Authors:  Yeqin Wang; Yoshinari Yamamoto; Suguru Shigemori; Takafumi Watanabe; Kazushi Oshiro; Xinyu Wang; Pengfei Wang; Takashi Sato; Shinichi Yonekura; Sachi Tanaka; Haruki Kitazawa; Takeshi Shimosato
Journal:  Mol Ther       Date:  2014-12-15       Impact factor: 11.454

8.  Cytosine-phosphate-guanosine-DNA induces CD274 expression in human B cells and suppresses T helper type 2 cytokine production in pollen antigen-stimulated CD4-positive cells.

Authors:  S Kubo; T Yamada; Y Osawa; Y Ito; N Narita; S Fujieda
Journal:  Clin Exp Immunol       Date:  2012-07       Impact factor: 4.330

9.  Preconditioning with intravenous colitic cell-free DNA prevents DSS-colitis by altering TLR9-associated gene expression profile.

Authors:  Györgyi Műzes; Ferenc Sipos; István Fűri; Miklós Constantinovits; Sándor Spisák; Barnabás Wichmann; Gábor Valcz; Zsolt Tulassay; Béla Molnár
Journal:  Dig Dis Sci       Date:  2014-09-13       Impact factor: 3.199

10.  The counter regulatory response induced by CpG oligonucleotides prevents bleomycin induced pneumopathy.

Authors:  Takeshi Kinjo; Koji Tomaru; Diana C Haines; Dennis M Klinman
Journal:  Respir Res       Date:  2012-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.